Topiramate Tablet, Film Coated
Product Images NDC 71205-214

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 71205-214). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-214-60 (25mg)

71205-214-60 (25mg)
Topiramate 25 mg film-coated tablets packaging label by Proficient Rx LP. The label indicates 90 tablets per package, with each tablet containing 25 mg of topiramate USP. The tablets are described as white, debossed, circular, with coding on both sides. Manufacturer is Sun Pharmaceutical Industries Limited, India. Storage instructions recommend 20°-25°C (68°-77°F). Label includes barcode, NDC 71205-214-90, and multiple batch identification areas.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of topiramate showing a bicyclic sugar-like skeleton with multiple oxygen atoms, methyl groups, and a sulfamate moiety attached. This structural formula represents the active ingredient topiramate.*
FDA Label Image

Figure-1jpg (Figure 1)

Figure-1jpg (Figure 1)
Kaplan-Meier plot displaying cumulative rates for time to first seizure over 500 days, comparing Topiramate 50 mg/day and 400 mg/day dosages. The graph shows cumulative rates on the vertical axis and time in days on the horizontal axis, with two curves representing different dosage groups.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar chart comparing change from baseline in average monthly migraine period rate across four groups: Placebo, Topiramate 50 mg/day, 100 mg/day, and 200 mg/day, for two studies labeled Study 10 and Study 11. The chart shows dose-dependent reductions in migraine rate with statistical significance indicated for the higher doses of Topiramate. Error bars represent standard error.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.